➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Dow
Medtronic
Boehringer Ingelheim
McKinsey

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 8,158,129

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,158,129
Title:Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
Abstract: The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. In alternative embodiments, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-.alpha.2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.
Inventor(s): Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), McBride; William J. (Boonton, NJ), Rossi; Edmund A. (Woodland Park, NJ)
Assignee: IBC Pharmaceuticals, Inc. (Morris Plains, NJ)
Application Number:13/178,092
Patent Claims:see list of patent claims

Details for Patent 8,158,129

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Hoffman-la Roche PEGASYS peginterferon alfa-2a SYRINGE 103964 002 2002-10-16   Start Trial IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-04-06 RX search
Hoffman-la Roche PEGASYS peginterferon alfa-2a VIAL; SUBCUTANEOUS 103964 001 2002-10-16   Start Trial IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-04-06 RX search
Schering SYLATRON peginterferon alfa-2b VIAL 103949 011 2001-01-19   Start Trial IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-04-06 RX search
Schering SYLATRON peginterferon alfa-2b VIAL 103949 010 2001-01-19   Start Trial IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-04-06 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
McKesson
Medtronic
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.